Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
A prospective stroke cohort associated preadmission benzodiazepine use with some poorer outcomes. The statistical conclusion depended partly on how baseline differences were handled.
A phase-one probe study found increased midazolam area under the curve during rucaparib treatment. A change in total exposure was not mirrored by a similar increase in peak concentration.
A randomized pediatric trial did not find diazepam superior to placebo for reported sleep bruxism. Improvement within a treated group therefore could not establish drug efficacy.
A review of refractory-epilepsy imaging discussed radiolabeled flumazenil as a receptor tracer. That application is different from administering flumazenil to reverse clinical sedation.
A registry-design paper proposed systematic observation of adult status epilepticus. It described intended measurements, not completed outcome evidence from the planned cohort.
A study of Irish primary-care dispensing found falling benzodiazepine and Z-drug rates from 2014 to 2022. Its comparison with England needs qualification because the underlying populations differed.
A retrospective pediatric ablation study found no significant inducibility difference among three anesthetic groups. Remimazolam’s higher BIS readings did not establish lesser clinical anesthesia.
A cross-sectional analysis associated both insomnia and benzodiazepine use with erectile dysfunction. Their combined association was not proof of a pharmacologic interaction.
A prospective eighty-patient comparison favored ketofol on several outcomes. Clinicians selected the regimen, so the study cannot attribute the entire difference to the drugs.
An opinion article asks for clearer interpretation of inpatient and residential tapering recommendations. It is commentary on a guideline, not a newly adopted replacement guideline or an outcome trial.
A fourteen-rabbit study found reduced tear production and ocular perfusion measures with two sedative combinations. Because the regimens differed in more than one component, the effects cannot be assigned to midazolam alone.
A review describes bone marrow as useful when conventional postmortem samples are compromised. Finding a benzodiazepine in marrow does not by itself reconstruct a corresponding antemortem blood level.
A large health-system study found that prior use was the strongest predictor of wartime benzodiazepine purchasing. That result distinguishes continuation of treatment from a new treatment response to conflict.
A randomized adult study found more hypotension with midazolam and more bradycardia with dexmedetomidine. Recovery time also differed, preventing a simple declaration that one regimen was safer in every respect.
A randomized dental study found better pain control with a combined premedication strategy. Its design did not isolate alprazolam’s independent contribution.
A quality-improvement project identified dosing discrepancies and amended local guidance. Early clinician confidence improved, but a completed outcome re-audit was still needed.
A small perioperative study found no detectable glucose difference between propofol–fentanyl and midazolam–fentanyl. Both groups received an opioid, which limits attribution to either sedative alone.
A young adult’s catatonia assessment illustrates why administration route and reassessment time matter. The later response did not establish that the first dose alone caused every improvement.
A laboratory comparison measured diazepam and three metabolites in aquatic products. Its results illustrate matrix-specific validation and should not be transferred directly to human blood testing.
A small crossover study used midazolam to examine CYP3A activity after red-ginseng supplementation. It did not find a clinically meaningful interaction under its tested conditions.
A community-pharmacy survey found substantial long-duration use and reported dose increases. Its design separates users’ descriptions from objectively demonstrated adverse drug reactions.
Interviews with 41 adults described several pathways to problematic benzodiazepine use. Participants’ explanations provide clinical context but do not establish how common each pathway is in the general population.
A small controlled simulator study found worse lane control after alprazolam and explored an experimental classifier. Its accuracy estimate concerns the study’s driving outcomes, rather than roadside diagnosis.
An adolescent with Niemann-Pick disease type C had recurrent catatonia, unsuccessful lorazepam treatment, and improvement during electroconvulsive therapy. A disease-specific case cannot establish the response expected in all catatonia.
A cefepime neurotoxicity case described a temporary EEG response to lorazepam, followed by recovery after several treatment changes. The sequence does not isolate lorazepam as the sole explanation for recovery.
In naturally sleeping rats, zolpidem and diazepam produced different patterns of hippocampal and prefrontal activity. Shared action at GABA-A receptors did not make their measured sleep-network effects identical.
A systematic review found substantial variation in pharmaceutical metabolite-to-drug ratios in hair. A ratio may aid interpretation, but it is not a universal conversion from a hair result to dose or timing.
The term diazepam-binding inhibitor refers to an endogenous protein in this paper. Elevated ACBP/DBI is not a laboratory finding of diazepam exposure.
A Parkinson disease review described clonazepam as an established option for REM sleep behavior disorder, but its discussion of a placebo-controlled trial was more cautious than its broad conclusions.
A small uncontrolled ganaxolone study concerns refractory seizures after earlier treatment, rather than a head-to-head test against benzodiazepines.